IBTA e-News September 2019 now out

By 27th September 2019 IBTA News
[30 September 2019] The IBTA's monthly e-News has been released and has emailed to all subscribers. To sign up to receive your copy, click here.

You can also read the IBTA e-News September 2019 edition in full online here.

Some of the highlights from this month's round-up:

  • Biotech company, Tocagen, has announced that their randomised, phase 3 clinical study evaluating their gene therapy, Toca 5, in patients with recurrent high-grade glioma did not achieve the primary aim of improving overall survival compared to standard-of-care treatment.
  • Bristol-Myers Squibb provides update on phase 3 Opdivo study, CheckMate-548, in patients with newly diagnosed MGMT-methylated glioblastoma. In this phase 3, randomised, CheckMate-548 trial, researchers are evaluating the addition of Opdivo to the current standard of care versus standard of care alone.
  • Ketogenic-type diets are high in fat and low in protein and carbohydrates; the modified Atkins diet is a less stringent version of a KD that still generates serum ketones in patients. The present study, published in Current Oncology, retrospectively examined the feasibility of attaining raised levels of ketones in body tissues (ketosis) in 29 patients with grades 2-4 glioma undergoing the KD during radiation and chemotherapy treatment.
  • Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide alone in patients with newly diagnosed, MGMT-methylated glioblastoma. This open-label, randomised, phase 3 CeTeG/NOA-09 study, published in The Lancet Oncology, was conducted in chemoradiotherapy-naïve adult patients with MGMT-methylated glioblastoma across 17 centres in Germany. The researchers saw significantly longer overall survival for those patients who received lomustine-temozolomide therapy compared to those on standard temozolomide alone.
  • A research team from the University of Georgia's Regenerative Bioscience Center has found that the molecule, Surfen, used to deliver insulin could also be used to treat glioblastoma. Their study, to be published in the FASEB Journal, shows for the first time, that the growth of invasive brain tumours, like glioblastoma, could be stifled by Surfen, which could help in the reduction or refinement of mainstream treatments, like radiation or chemotherapy.
  • In a publication in the Journal of Neuro-Oncology, Oncoceutics Inc reports a complete response and other forms of clinical benefit in 18 paediatric and adult H3 K27M-mutant glioma patients treated with ONC201 on expanded access protocols. Overall findings include disease stabilisation and radiographic regressions after patients started ONC201 treatment, which are uncharacteristic for the disease course.
  • In a publication in Nature, scientists have reported how tumour cells can plug into, and feed off, the brain's complex network of neurons, according to a trio of studies. The researchers say that the findings suggest the nervous system plays an important role in cancer growth.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.

let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.